The discovery of the role of epidermal growth factor receptor (EGFR) overexpression in the pathogenesis of HNC has opened new pathways in the development of novel therapeutic agents for the targeted treatment of recurrent and/or metastatic head and neck squamous cell carcinoma. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.